Core Viewpoint - The company, Zhenbaodao, announced that its wholly-owned subsidiary, Bozhou Chinese Medicine Material Trading Center Co., Ltd., plans to acquire a 49% stake in its controlling subsidiary, Guizhou Shennong Valley, for a total price of 49 million RMB plus interest from the fund's regulatory account during the investment period [1] Group 1 - The acquisition will result in Bozhou Trading Center holding 100% of Guizhou Shennong Valley after the transaction is completed [1] - The transaction does not constitute a related party transaction or a major asset restructuring, and therefore does not require approval from the company's board of directors or shareholders' meeting [1]

Core Viewpoint - The company has received approval from the National Medical Products Administration for clinical trials of a new herbal medicine, Compound Qilan Oral Solution, aimed at treating children aged 4-12 with external wind-heat symptoms [1] Group 1: Product Development - The Compound Qilan Oral Solution is an independently developed traditional Chinese medicine by the company, derived from the classic formula "Yinqiao San" from the Qing Dynasty [1] - This product is part of the company's respiratory disease medication line and represents one of its key offerings [1] Group 2: Financial Aspects - The projected sales revenue for the Compound Qilan Oral Solution in 2024 is estimated to be 212 million yuan [1] - The company has invested approximately 15 million yuan in research and development for this product to date [1]

Core Viewpoint - The company received a shareholder inquiry letter from the China Securities Investor Service Center regarding compliance with disclosure and approval procedures related to a significant transaction that generated substantial profits exceeding regulatory thresholds [1][2][3]. Group 1: Transaction Details - The company reported a financial net gain of 420 million yuan from a transaction, which represents over 50% of the company's audited net profit of 185 million yuan for 2022 [1][3]. - The transaction's total amount was 425 million yuan, and it was noted that the transaction's profit exceeded the regulatory requirement of 5 million yuan [3]. Group 2: Regulatory Compliance Issues - The company faced scrutiny due to a warning letter from the Heilongjiang Securities Regulatory Bureau, which identified non-operational fund occupation by the controlling shareholder amounting to 80 million yuan, returned in February 2024 [2]. - The company failed to timely disclose and seek shareholder approval for the transaction, which was only addressed in a board meeting held on April 1, 2025, with subsequent disclosure on April 2, 2025 [3]. Group 3: Measures for Improvement - The company has implemented a comprehensive review and revision of its information disclosure management system to ensure compliance with standards, processes, and responsibilities [4]. - Internal controls have been strengthened, emphasizing the importance of compliance with disclosure regulations and enhancing the effectiveness of internal governance [5][6]. - The company has initiated training programs for personnel involved in information disclosure to improve their understanding of legal requirements and enhance compliance awareness [6][7].

关于中证中小投资者服务中心《股东质询函》的 回复公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 证券代码：603567 证券简称：珍宝岛 公告编号：临 2025-039 黑龙江珍宝岛药业股份有限公司 黑龙江珍宝岛药业股份有限公司（以下简称"公司"）近日收到中证中小投 资者服务中心（以下简称"投服中心"）的《股东质询函》（投服中心行权函【2025】 11 号），投服中心对公司 2023 年 8 月转让子公司股权并于近期补充披露的违规 操作事项提出质询。现就相关问题回复如下： 一、《上海证券交易所股票上市规则》(2023 年 2 月修订)6.1.3 条规定,交 易产生的利润占上市公司最近一个会计年度经审计净利润的 50%以上，且绝对金 额超过 500 万元，上市公司除应当及时披露外，还应当提交股东大会审议。根 据公告披露，本次交易完成后获得财务净收益 4.2 亿元,2022 年，你公司归属于 上市公司股东的净利润为 1.85 亿元,交易产生的利润占最近一个会计年度经审 计净利润的 50%以上，且绝对金额超过 500 万元。 ...

Core Viewpoint - The 90th National Pharmaceutical Trade Fair showcased Heilongjiang Zhenbaodao Pharmaceutical Co., Ltd., highlighting its brand, high-value product matrix, and ecological win-win philosophy [3][4] Group 1: Product Showcase - Zhenbaodao Pharmaceutical exhibited high-quality product lines focusing on cardiovascular, respiratory, and anti-infection treatment areas, including key products like Injection Blood Setong 100mg and Xuechuang Capsule [3] - The company has developed a dual-driven system of "Traditional Chinese Medicine + Chemical Medicine," featuring products such as Compound Qilan Oral Liquid and Injection Ammonium Bromide [3] Group 2: Marketing Strategy - The company emphasized its 2025 "Guangshen Tuo" marketing strategy, which segments regional markets based on product attributes and promotes a model of "recruiting merchants, finding merchants, and servicing merchants" to enhance terminal coverage and sales efficiency [4] - Zhenbaodao Pharmaceutical established a three-tier academic promotion system, integrating medical, market, and data teams to monitor industry trends and provide precise marketing strategies [4] Group 3: Collaborative Ecosystem - The participation in the trade fair demonstrated the company's competitive product pipeline and industrial layout, aiming to build a comprehensive ecosystem of strategic collaboration, resource sharing, and value co-creation [4] - The company plans to continue driving innovation and collaboration, positioning itself to lead the pharmaceutical industry towards higher value creation [4]

Core Insights - The company is advancing its strategic layout and business progress through product pipeline expansion, technological innovation, and industrial collaboration, showcasing strong resilience and growth potential [1] Group 1: Product Innovation and Core Competitiveness - The company has been upgrading its product pipeline and increasing R&D investment, with its subsidiary obtaining approval for 16 chemical drug listings, covering major diseases with significant market potential [2] - The introduction of AI visual inspection technology for production monitoring and the development of a smart trading platform for traditional Chinese medicine (TCM) are enhancing the company's competitive edge [2] Group 2: Industry Ecosystem Development - The company is promoting industrial cooperation projects to boost local economic development, linking over 10,000 quality herbal merchants through its trading center [3] - A strategic partnership with a leading TCM company has strengthened the supply capacity of herbal medicines, enhancing the trading center's competitiveness [3] Group 3: Digital Transformation and Supply Chain Management - The company initiated the Guizhou Shennong Valley project to create a standardized, digitalized, and networked industry ecosystem, establishing 6 standardized planting bases covering 4,400 acres [4] - The implementation of a digital management platform ensures traceability and quality control of herbal medicines, benefiting both product quality and farmer income [4] Group 4: Brand Empowerment and Market Expansion - The company has developed a comprehensive marketing system to enhance brand influence, showcasing its diverse product pipeline at national trade events [5] - Core products have excelled in national TCM procurement, reinforcing market position through quality advantages and innovative strategies [5] Group 5: Sustainable Development Strategy - The company has proposed a dual-engine strategy focusing on "scientific innovation and resource aggregation," aiming to enhance evidence-based medicine research and smart manufacturing [6] - The goal is to modernize and internationalize traditional Chinese medicine, targeting a marketing scale of 10 billion and creating a health industry ecosystem [6] Group 6: Overall Growth Path - The company demonstrates a clear growth trajectory and momentum through strategic focus, product innovation, and ecosystem collaboration, addressing market concerns amid regulatory challenges [7][8]

证券代码：603567 证券简称：珍宝岛 公告编号：临 2025-038 黑龙江珍宝岛药业股份有限公司 关于为全资子公司银行贷款展期提供担保的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ●被担保人名称：哈尔滨珍宝制药有限公司（以下简称"哈珍宝"），系黑龙 江珍宝岛药业股份有限公司（以下简称"公司"）的全资子公司。 ●本次担保金额为不超过人民币 1.70 亿元，截至公告披露日，公司已实际 为哈珍宝提供的担保余额为人民币 9.21 亿元（含本次担保）。 ●截至本公告披露日，公司实际对外担保总额人民币 16.01 亿元（含本次担 保），全部是公司对全资子公司进行的担保。 ●本次担保无反担保。 ●公司无对外担保逾期的情况。 公司全资子公司哈珍宝于 2024 年 5 月 15 日向哈尔滨联合农村商业银行股份 有限公司呼兰支行（以下简称"哈联合农村商业银行"）申请 1.70 亿元人民币贷 款，贷款期限为 12 个月，公司为哈珍宝上述贷款事项提供连带责任保证担保。 （具体内容详见公司于 2024 年 5 月 16 ...

Core Points - The company held its 18th meeting of the 5th Supervisory Board on May 13, 2025, where it approved the use of idle raised funds to temporarily supplement working capital [1][2] - The Supervisory Board concluded that the approval process for using up to RMB 300 million of idle raised funds complies with relevant laws and regulations, does not change the purpose of the raised funds, and does not harm shareholder interests [1][2] Summary by Sections Meeting Details - The meeting was conducted in person at the company's conference room with three supervisors present, chaired by Mr. Lan Peibao [1] Resolution Passed - The resolution to use idle raised funds was unanimously approved by the Supervisory Board with three votes in favor and no votes against or abstentions [2]

证券代码：603567 证券简称：珍宝岛 公告编号：临 2025-037 黑龙江珍宝岛药业股份有限公司 关于归还募集资金并继续使用部分闲置募集资金 暂时补充流动资金的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 （具体内容详见公司于 2024 年 9 月 24 日在上海证券交易所网站 www.sse.com.cn 披露的临 2024-062 号公告） 二、募集资金投资项目的基本情况 截至 2024 年 12 月 31 日，公司已累计使用募集资金 831,349,109.07 元，暂 时补充流动资金金额为 230,000,000 元，累计利息收入 4,937,710.02 元，累计 手续费支出 20,778.66 元，募集资金账户余额为 160,807,954.51 元。具体募集 资金使用情况如下: | | | | | | 重要内容提示： ? 黑龙江珍宝岛药业股份有限公司（以下简称"公司"）归还募集资金 第十八次会议审议通过之日起不超过 12 个月。 一、募集资金基本情况 经中国证券监督管理委员会出具的《关于核准黑龙江珍 ...

证券代码：603567 证券简称：珍宝岛 公告编号：临 2025-036 监事会认为：公司本次使用不超过人民币 30,000 万元闲置募集资金暂时补 充流动资金相关审批程序符合《上海证券交易所股票上市规则》《上市公司监管 指引第 2 号——上市公司募集资金管理和使用的监管要求》等相关法律、法规和 规范性文件的规定，未改变募集资金用途，未影响募集资金的投资计划，不存在 损害股东利益的情形，符合公司经营发展需要。公司监事会一致同意本议案。 表决结果：同意 3 票，反对 0 票，弃权 0 票。 具体内容详见同日在上海证券交易所网站（www.sse.com.cn）披露的《黑龙 江珍宝岛药业股份有限公司关于归还募集资金并继续使用部分闲置募集资金暂 时补充流动资金的公告》（公告编号：临 2025-037 号）。 特此公告。 黑龙江珍宝岛药业股份有限公司 第五届监事会第十八次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 黑龙江珍宝岛药业股份有限公司（以下简称"公司"）第五届监事会第十八 次会议于 2025 年 5 月 13 ...